Psoriatic Arthritis Market, By Drug Class (DMARD, NSAIDs, Biologics, and Others), By Product Type (OTC and Prescriptions), By Route of Administration (Oral, Topical, and Injectable), and By Region - Trends, Analysis, and Forecast till 2029

Report Code: PMI452020 | Publish Date: August 2023 | No. of Pages: 168

Global Psoriatic Arthritis Market Companies

  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Novartis International AG
  • Eli Lilly and Company
  • Pfizer, Inc.
  • UCB S.A. Strategic.

Recent News:

  • In June 2021, AbbVie disclosed that the Ministry of Health and Welfare approved RINVOQ (upadacitinib, 15 mg), a sublingual, once-daily  reversible JAK antagonist, for  use in adults with severe psoriatic arthritis (RP) who have had an individual or adverse reaction to methimazole or other disease-modifying antirheumatic drugs (DMARDs).
  • In August 2019, Can-Fite announced an agreement with Kyongbo Pharm., to distribute Piclidenoson, Can-lead Fite’s candidate, to patients with PsA  in  Korea.